Search

Your search keyword '"Aihua Zang"' showing total 2 results
Start Over Author "Aihua Zang" Journal plos one
2 results on '"Aihua Zang"'

1. SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.

Author

Liu Huang, Tao Zhang, Conghua Xie, Xin Liao, Qianqian Yu, Jueping Feng, Hong Ma, Jing Dai, Min Li, Jigui Chen, Aihua Zang, Qian Wang, Shuwang Ge, Kai Qin, Juan Cai, and Xianglin Yuan

Subjects
Medicine, Science
Abstract

Rapid response to chemotherapy in metastatic colorectal cancer (mCRC) patients (response within 12 weeks of chemotherapy) may increase the chance of complete resection and improved survival. Few molecular markers predict irinotecan-induced rapid response and survival. Single-nucleotide polymorphisms (SNPs) in solute carrier genes are reported to correlate with the variable pharmacokinetics of irinotecan and folate in cancer patients. This study aims to evaluate the predictive role of 3 SNPs in mCRC patients treated with irinotecan and fluoropyrimidine-containing regimens.Three SNPs were selected and genotyped in 137 mCRC patients from a Chinese prospective multicenter trial (NCT01282658). The chi-squared test, univariate and multivariable logistic regression model, and receiver operating characteristic analysis were used to evaluate correlations between the genotypes and rapid response. Kaplan-Meier survival analysis and Cox proportional hazard models were used to evaluate the associations between genotypes and survival outcomes. Benjamini and Hochberg False Discovery Rate correction was used in multiple testing.Genotype GA/AA of SNP rs2306283 of the gene SLCO1B1 and genotype GG of SNP rs1051266 of the gene SLC19A1 were associated with a higher rapid response rate (odds ratio [OR] =3.583 and 3.521, 95%CI =1.301-9.871 and 1.271-9.804, p=0.011 and p=0.013, respectively). The response rate was 70% in patients with both genotypes, compared with only 19.7% in the remaining patients (OR = 9.489, 95%CI = 2.191-41.093, Fisher's exact test p=0.002). Their significances were all maintained even after multiple testing (all p c < 0.05). The rs2306283 GA/AA genotype was also an independent prognostic factor of longer progression-free survival (PFS) (hazard ratio = 0.402, 95%CI = 0.171-0.945, p=0.037). None of the SNPs predicted overall survival.Polymorphisms of solute carriers' may be useful to predict rapid response to irinotecan plus fluoropyrimidine and PFS in mCRC patients.

Published
2013
Full Text
View/download PDF

2. SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer

Author

Jing Dai, Shuwang Ge, Min Li, Aihua Zang, Qian Wang, Hong Ma, Tao Zhang, Juan Cai, Xianglin Yuan, Liu Huang, Jueping Feng, Kai Qin, Conghua Xie, Qianqian Yu, Xin Liao, and Jigui Chen

Subjects
Male, Oncology, Time Factors, Colorectal cancer, medicine.medical_treatment, Organic Anion Transporters, lcsh:Medicine, Pharmacology, Linkage Disequilibrium, Metastasis, Reduced Folate Carrier Protein, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Neoplasm Metastasis, lcsh:Science, Multidisciplinary, Liver-Specific Organic Anion Transporter 1, Middle Aged, Treatment Outcome, Female, Colorectal Neoplasms, Research Article, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Antineoplastic Agents, Irinotecan, Polymorphism, Single Nucleotide, Young Adult, Internal medicine, medicine, Humans, Survival analysis, Aged, Chemotherapy, business.industry, lcsh:R, Cancer, medicine.disease, Survival Analysis, digestive system diseases, Pyrimidines, Haplotypes, Pharmacogenetics, Camptothecin, lcsh:Q, business
Abstract

Background Rapid response to chemotherapy in metastatic colorectal cancer (mCRC) patients (response within 12 weeks of chemotherapy) may increase the chance of complete resection and improved survival. Few molecular markers predict irinotecan-induced rapid response and survival. Single-nucleotide polymorphisms (SNPs) in solute carrier genes are reported to correlate with the variable pharmacokinetics of irinotecan and folate in cancer patients. This study aims to evaluate the predictive role of 3 SNPs in mCRC patients treated with irinotecan and fluoropyrimidine-containing regimens. Materials and Methods Three SNPs were selected and genotyped in 137 mCRC patients from a Chinese prospective multicenter trial (NCT01282658). The chi-squared test, univariate and multivariable logistic regression model, and receiver operating characteristic analysis were used to evaluate correlations between the genotypes and rapid response. Kaplan-Meier survival analysis and Cox proportional hazard models were used to evaluate the associations between genotypes and survival outcomes. Benjamini and Hochberg False Discovery Rate correction was used in multiple testing Results Genotype GA/AA of SNP rs2306283 of the gene SLCO1B1 and genotype GG of SNP rs1051266 of the gene SLC19A1 were associated with a higher rapid response rate (odds ratio [OR] =3.583 and 3.521, 95%CI =1.301-9.871 and 1.271-9.804, p=0.011 and p=0.013, respectively). The response rate was 70% in patients with both genotypes, compared with only 19.7% in the remaining patients (OR = 9.489, 95%CI = 2.191-41.093, Fisher's exact test p=0.002). Their significances were all maintained even after multiple testing (all p c < 0.05). The rs2306283 GA/AA genotype was also an independent prognostic factor of longer progression-free survival (PFS) (hazard ratio = 0.402, 95%CI = 0.171-0.945, p=0.037). None of the SNPs predicted overall survival. Conclusions Polymorphisms of solute carriers’ may be useful to predict rapid response to irinotecan plus fluoropyrimidine and PFS in mCRC patients. Trial Registry ClinicalTrials.gov NCT01282658 http://www.clinicaltrials.gov/ct2/show/NCT01282658

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results